Free shipping on all orders over $ 500

Atamparib (RBN-2397)

Cat. No. M9602
Atamparib (RBN-2397) Structure
Synonym:

Atamparib

Size Price Availability Quantity
5mg USD 440  USD440 In stock
10mg USD 740  USD740 In stock
25mg USD 1080  USD1080 In stock
50mg USD 1600  USD1600 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Atamparib (RBN-2397) is a potent and orally active NAD+ competitive inhibitor of PARP7 (IC50<3 nM). RBN-2397 selectively binds to PARP7 (Kd=0.001 μM) and restores interferon (Type I) signaling. RBN-2397 (0.0001-100 μM; 24 hours) inhibits cells proliferation with an IC50 value of 20 nM in NCI-H1373 lung cancer cells.

Atamparib (RBN-2397) (3-100 mg/kg; oral; once daily) 24-32 days treatment induces tumor-specific adaptive immune memory in CT26 syngeneic model with durable complete responses in CT26 tumor-bearing BALB/c mice.

Chemical Information
Molecular Weight 523.43
Formula C20H23F6N7O3
CAS Number 2381037-82-5
Solubility (25°C) DMSO ≥ 100 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Joseph M Gozgit, et al. PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity

Related PARP Products
DSB-1522

DSB-1522 is a PARP1 inhibitor that can be used in tumor-related studies.

DM-5167

DM-5167 is a PARP1 inhibitor that can be used in studies related to triple negative breast cancer.

NMS-03305293

NMS-03305293 is a PARP inhibitor with high selectivity for PARP1 isoforms and low DNA capture effect, which specifically kills BRCA mutated tumor cells. In addition, NMS-03305293 can penetrate the blood-brain barrier and can be used in studies related to CNS tumors and brain metastatic tumors.

SNV1521

SNV1521 is a potential best-in-class (BIC), highly selective and CNS-permeable PARP1 inhibitor.

Basroparib

Basroparib is an orally active selective inhibitor of end-anchor polymerase (TNKS) and an inhibitor of ribose polymerase (PARP) with antitumor activity.

  Catalog
Abmole Inhibitor Catalog




Keywords: Atamparib (RBN-2397), Atamparib supplier, PARP, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.